Current Literature

  1. Blok JL, van Hattem S, Jonkman MF, Horvath B. systemic therapy with immunosuppressive agents and retinoids in hidradentitis suppurativa: a systemic review. BrJDermatol 2013;168(2):243-52.
  2. Canoui-Poitrine F, LeThuaut A, Revuz JE, et al. identification of three hidradenitis suppurativ phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol 2013;1506-11.
  3. Danby FW. Commentary: unroofing for hidradenitis suppurativa, why and how. J Am Acad Dermatol 2010 Sep;63(3):481-3.
  4. Danby FW, Jemec GB, Marsch WC, vonLaffert M. Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol 2013 May;168(5):1034-9.
  5. Danby FW. Turning acne on/off via mTORC1. Exp Dermatol 2013 Jul;22(7):505-6. This article is Open Access at http://onlinelibrary.wiley.com/doi/10.1111/exd.12180/pdf
  6. DeSouza A, Solomon GE, Strober BE. SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate. Bull NYU Hosp Jt Dis 2011;69(2): 185-7.
  7. Finlay AY, Khan GK. Dermatology life quality index (DLQI): a simple practical measure for routine clinical use. Clinical and Exp Dermatol 194;19:210-6.
  8. Ingram JR, Piguet V. Phenotypic heterogeneity in hidradenitis suppurativa (acne inversa): classification is an essential step towards personal therapy. J Invest Dermatol 2013;133:1453-6.
  9. Jemec G, Ruvez J, Leyden J (eds). Hidradenitis Suppurativa. 1st Ed. Heidelberg, Germany. Springer, 2006.
  10. Kimball AB, Gu Y, Okun M. Treatment of moderate to severe hidradenitis suppurativa. Ann Int Med 2013;159:72-3.
  11. Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Int Med 2012;158:846-55.
  12. Marzano AV, Trevisan V, Gattorno M, et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associate with a novel mutation of the PSTPIPI gene. JAMA Dermatol 2013;149:762-4.
  13. Melnik BC, Plewig G. Impaired Notch-MKP-1 signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from transitional biology. Exp Dermatol. 2-13;22:172-7.
  14. Melnik BC, Zouboulis CC. Potential role of FoxO1 and mTORC1 in the pathogenesis of Western diet-induced acne. Exp Dermatol 2013 May;22(5):311-5. This article is Open Access at http://onlinelibrary.wiley.com/doi/10.1111/exd.12142/pdf
  15. Rambhatia PV, Lim HW, Hamzavi I. A systematic review of treatments for hidradenitis suppurativa. Arch Dermatol 2012;148(4):439-46.
  16. Sartorius K, Lapins T, Emtestam L, Jemec G. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149(1):211-3.
  17. Wolkenstein P, Loundou A, Barrau K, Auquier P, Ruvez J. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56(4):621-3.
  18. Scheinfeld N. Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients. Online Journal. 2013.